Philips Q3 sales reach €4.4bn as orders rise 8%
Key points
- Philips reported third-quarter sales of approximately €4.4 billion, with comparable sales increasing 3% and order intake growing 8%.
- Adjusted EBITA margin improved to 13.0%, while operating cash flow reached €544 million and free cash flow totaled €384 million.
- Philips maintained its 2026 comparable sales growth forecast of 3%–4.5% and adjusted EBITA margin guidance of 13.5%–14.%.
Philips (NYSE:PHG) reported third-quarter 2026 sales of approximately €4.4 billion, with comparable sales increasing 3% and order intake rising 8%, supported by growth in its healthcare technology businesses.
The company's adjusted EBITA margin increased 70 basis points to 13%, while income from operations reached €165 million, reflecting higher sales, productivity measures and improved gross margins.
"We delivered an excellent 8% comparable order intake, led by broad-based order momentum in Diagnosis & Treatment," said Philips Chief Executive Officer Roy Jakobs.
Operating cash flow increased to €544 million and free cash flow reached €384 million, while productivity initiatives generated €170 million in quarterly savings and Philips issued €650 million in fixed-rate notes due in 2034.
Philips maintained its 2026 comparable sales growth forecast of 3%–4.5%, adjusted EBITA margin guidance of 13.5%–14% and free cash flow outlook of €1.5 billion–€1.7 billion.
Connected Care comparable sales increased 5% and Personal Health grew 8%, while Diagnosis & Treatment sales remained flat as growth in Image Guided Therapy offset weaker Precision Diagnosis performance.
Philips continues investing in medical imaging, patient monitoring and consumer health technologies, while its Respironics business reached an agreement in principle with the US Department of Justice concerning previously disclosed product recall investigations.
